Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 74,764 shares of Invivyd stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $0.47, for a total value of $35,139.08. Following the completion of the transaction, the director now owns 3,840,146 shares of the company's stock, valued at $1,804,868.62. The trade was a 1.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Terrance Mcguire also recently made the following trade(s):
- On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73.
- On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00.
- On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00.
Invivyd Stock Performance
Shares of IVVD stock opened at $0.43 on Friday. The stock's 50-day moving average is $0.79 and its two-hundred day moving average is $1.03. Invivyd, Inc. has a 1 year low of $0.43 and a 1 year high of $5.20. The firm has a market cap of $51.40 million, a price-to-earnings ratio of -0.22 and a beta of 0.53.
Institutional Inflows and Outflows
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
A number of hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC purchased a new stake in Invivyd in the third quarter valued at approximately $27,000. SG Americas Securities LLC raised its position in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock valued at $42,000 after purchasing an additional 25,201 shares during the last quarter. XTX Topco Ltd boosted its stake in Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after purchasing an additional 15,376 shares during the period. Cornercap Investment Counsel Inc. purchased a new position in Invivyd during the 2nd quarter worth $86,000. Finally, Rhumbline Advisers increased its stake in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock valued at $92,000 after purchasing an additional 82,164 shares during the period. Hedge funds and other institutional investors own 70.36% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, November 20th. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a report on Thursday, November 21st. EF Hutton Acquisition Co. I upgraded Invivyd to a "strong-buy" rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley lowered their price target on Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Invivyd currently has a consensus rating of "Buy" and an average price target of $7.89.
Check Out Our Latest Stock Analysis on IVVD
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
